Related Experiment Videos
Lorcainide (R 15 889), a first review
Acta Cardiologica
|January 1, 1981
Summary
Lorcainide hydrochloride, a novel antiarrhythmic drug, effectively suppresses ventricular arrhythmias by impairing sodium channels with minimal hemodynamic impact. Its oral absorption and long half-life offer therapeutic advantages, though dose-dependent side effects require monitoring.
Area of Science:
- Pharmacology
- Cardiology
- Clinical Therapeutics
Background:
- Lorcainide hydrochloride is a new antiarrhythmic agent possessing local anesthetic properties.
- Its mechanism of action involves the impairment of fast sodium conductance, crucial for cardiac electrical activity.
Purpose of the Study:
- To review the pharmacological profile and clinical efficacy of lorcainide hydrochloride.
- To assess its potential in managing various cardiac arrhythmias, particularly ventricular arrhythmias and pre-excitation syndromes.
Main Methods:
- Review of pharmacological data on lorcainide hydrochloride.
- Analysis of preliminary clinical experiences and observed response rates in patients with arrhythmias.
Main Results:
- Lorcainide hydrochloride effectively suppresses reentry phenomena and ectopic pacemaker activity, especially in the ventricles.
- The drug exhibits negligible depressant effects on hemodynamic parameters and has minimal toxicity.
- Oral absorption is good, and the elimination half-life is long; QRS widening correlates with plasma levels.
Conclusions:
- Lorcainide hydrochloride shows promise for supraventricular arrhythmias but is primarily indicated for pre-excitation syndromes and ventricular arrhythmias due to high response rates.
- Side effects are generally harmless and dose-dependent, warranting clinical attention.